705 reports of this reaction
1.4% of all MYCOPHENOLIC ACID reports
#20 most reported adverse reaction
TRANSPLANT REJECTION is the #20 most commonly reported adverse reaction for MYCOPHENOLIC ACID, manufactured by Novartis Pharmaceuticals Corporation. There are 705 FDA adverse event reports linking MYCOPHENOLIC ACID to TRANSPLANT REJECTION. This represents approximately 1.4% of all 51,116 adverse event reports for this drug.
MYCOPHENOLIC ACID has an overall safety score of 88 out of 100. Patients taking MYCOPHENOLIC ACID who experience transplant rejection should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TRANSPLANT REJECTION is a less commonly reported adverse event for MYCOPHENOLIC ACID, but still significant enough to appear in the safety profile.
In addition to transplant rejection, the following adverse reactions have been reported for MYCOPHENOLIC ACID:
The following drugs have also been linked to transplant rejection in FDA adverse event reports:
TRANSPLANT REJECTION has been reported as an adverse event in 705 FDA reports for MYCOPHENOLIC ACID. This does not prove causation, but indicates an association observed in post-market surveillance data.
TRANSPLANT REJECTION accounts for approximately 1.4% of all adverse event reports for MYCOPHENOLIC ACID, making it a notable side effect.
If you experience transplant rejection while taking MYCOPHENOLIC ACID, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.